IMMUTEP LTD-SP ADR (IMMP) Stock Fundamental Analysis

NASDAQ:IMMP • US45257L1089

2.8 USD
+0.06 (+2.19%)
Last: Feb 27, 2026, 08:11 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IMMP. IMMP was compared to 520 industry peers in the Biotechnology industry. IMMP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. IMMP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year IMMP has reported negative net income.
  • IMMP had a negative operating cash flow in the past year.
  • In the past 5 years IMMP always reported negative net income.
  • IMMP had a negative operating cash flow in each of the past 5 years.
IMMP Yearly Net Income VS EBIT VS OCF VS FCFIMMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • IMMP has a Return On Assets of -24.06%. This is in the better half of the industry: IMMP outperforms 71.65% of its industry peers.
  • With a decent Return On Equity value of -25.43%, IMMP is doing good in the industry, outperforming 78.74% of the companies in the same industry.
Industry RankSector Rank
ROA -24.06%
ROE -25.43%
ROIC N/A
ROA(3y)-29.13%
ROA(5y)-31.07%
ROE(3y)-31.51%
ROE(5y)-33.92%
ROIC(3y)N/A
ROIC(5y)N/A
IMMP Yearly ROA, ROE, ROICIMMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for IMMP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMMP Yearly Profit, Operating, Gross MarginsIMMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20K -40K -60K -80K -100K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • IMMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • IMMP has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for IMMP has been increased compared to 5 years ago.
  • Compared to 1 year ago, IMMP has a worse debt to assets ratio.
IMMP Yearly Shares OutstandingIMMP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
IMMP Yearly Total Debt VS Total AssetsIMMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 32.47 indicates that IMMP is not in any danger for bankruptcy at the moment.
  • IMMP has a better Altman-Z score (32.47) than 92.72% of its industry peers.
  • IMMP has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • IMMP's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. IMMP outperforms 49.62% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 32.47
ROIC/WACCN/A
WACC9.35%
IMMP Yearly LT Debt VS Equity VS FCFIMMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 18.86 indicates that IMMP has no problem at all paying its short term obligations.
  • IMMP's Current ratio of 18.86 is amongst the best of the industry. IMMP outperforms 95.40% of its industry peers.
  • A Quick Ratio of 18.86 indicates that IMMP has no problem at all paying its short term obligations.
  • IMMP has a better Quick ratio (18.86) than 95.40% of its industry peers.
Industry RankSector Rank
Current Ratio 18.86
Quick Ratio 18.86
IMMP Yearly Current Assets VS Current LiabilitesIMMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for IMMP have decreased strongly by -14.43% in the last year.
  • Looking at the last year, IMMP shows a very negative growth in Revenue. The Revenue has decreased by -49.75% in the last year.
  • IMMP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -66.35% yearly.
EPS 1Y (TTM)-14.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.44%
Revenue 1Y (TTM)-49.75%
Revenue growth 3Y-38.18%
Revenue growth 5Y-66.35%
Sales Q2Q%-18.07%

3.2 Future

  • Based on estimates for the next years, IMMP will show a very strong growth in Earnings Per Share. The EPS will grow by 27.63% on average per year.
  • The Revenue is expected to grow by 128.81% on average over the next years. This is a very strong growth
EPS Next Y-39.92%
EPS Next 2Y-24.38%
EPS Next 3Y8.6%
EPS Next 5Y27.63%
Revenue Next Year312.29%
Revenue Next 2Y-11.11%
Revenue Next 3Y184.31%
Revenue Next 5Y128.81%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IMMP Yearly Revenue VS EstimatesIMMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
IMMP Yearly EPS VS EstimatesIMMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IMMP. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMMP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMMP Price Earnings VS Forward Price EarningsIMMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMMP Per share dataIMMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.38%
EPS Next 3Y8.6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for IMMP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IMMUTEP LTD-SP ADR

NASDAQ:IMMP (2/27/2026, 8:11:05 PM)

2.8

+0.06 (+2.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)07-29
Inst Owners45.28%
Inst Owner Change-18.27%
Ins Owners2.56%
Ins Owner ChangeN/A
Market Cap412.14M
Revenue(TTM)60.10K
Net Income(TTM)-43.87M
Analysts82.22
Price Target3.56 (27.14%)
Short Float %3.87%
Short Ratio5.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.01%
PT rev (3m)45.17%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-7.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)20.32%
Revenue NY rev (3m)424.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10779.93
P/FCF N/A
P/OCF N/A
P/B 3.36
P/tB 3.52
EV/EBITDA N/A
EPS(TTM)-0.29
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0
BVpS0.83
TBVpS0.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.06%
ROE -25.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.13%
ROA(5y)-31.07%
ROE(3y)-31.51%
ROE(5y)-33.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 1556.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.86
Quick Ratio 18.86
Altman-Z 32.47
F-Score2
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.44%
EPS Next Y-39.92%
EPS Next 2Y-24.38%
EPS Next 3Y8.6%
EPS Next 5Y27.63%
Revenue 1Y (TTM)-49.75%
Revenue growth 3Y-38.18%
Revenue growth 5Y-66.35%
Sales Q2Q%-18.07%
Revenue Next Year312.29%
Revenue Next 2Y-11.11%
Revenue Next 3Y184.31%
Revenue Next 5Y128.81%
EBIT growth 1Y-12.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.35%
EBIT Next 3Y6.45%
EBIT Next 5Y32.55%
FCF growth 1Y-10.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.95%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUTEP LTD-SP ADR / IMMP FAQ

What is the ChartMill fundamental rating of IMMUTEP LTD-SP ADR (IMMP) stock?

ChartMill assigns a fundamental rating of 3 / 10 to IMMP.


Can you provide the valuation status for IMMUTEP LTD-SP ADR?

ChartMill assigns a valuation rating of 0 / 10 to IMMUTEP LTD-SP ADR (IMMP). This can be considered as Overvalued.


How profitable is IMMUTEP LTD-SP ADR (IMMP) stock?

IMMUTEP LTD-SP ADR (IMMP) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for IMMP stock?

The Earnings per Share (EPS) of IMMUTEP LTD-SP ADR (IMMP) is expected to decline by -39.92% in the next year.